Subacute cutaneous lupus erythematosus associated with interferon beta-1a

Lancet

Volumn 352, Issue 9143, 1998, Pages 1825-1826

  Nousari, Hossein C ^a   Kimyai Asadi, Arash ^b   Tausk, Francisco A ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; BETA1A INTERFERON; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; INFLAMMATORY DISEASE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN LUPUS ERYTHEMATOSUS; SUN EXPOSURE;

EID: 0032488366     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79887-1     Document Type: Article

References (5)

1. 1 Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995; 105: 31-57.
2. 2 Graninger WB, Hassfeld W, Pesau BB, et al. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991; 18: 1621-22.
3. 3 Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon Beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
4. 4 Colosimo C, Pozzilli C, Frontomi M, et al. No increase of serum autoantibodies during therapy with recombinant human interferon-β1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 1997; 96: 372-74.
5. 5 Linden D. Severe Raynaud's phenomenon associated with interferon-β treatment for multiple sclerosis. Lancet 1998; 352: 878-79.